Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering.
Traditional cancer therapy has focused on removal or destruction of tumors cells by surgery, radiation and rather non-selective types of chemotherapy. Surgery and radiation are often effective with tumors which are localized and have not metastasized to multiple sites throughout the body.
Intensive research and clinical trial activity have led to a number of targeted treatments, using novel pathways and signaling, that have achieved results representing a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer.
One promising area is a class of drugs known as tyrosine kinase inhibitors, which phosphorylate specific amino acids on substrate enzymes, changes that subsequently alter signal transduction leading to downstream changes in cellular biology. This report examines and analyzes the three dozen therapeutic drugs that are defining the TKI oncology space.
What is the market share of approved TKI therapeutics?
What is the global supply picture for targeted TKI therapeutics?
Who are the market leaders, by Indication? by Product?
What is the therapeutic TKI coverage across all oncology indications?
What are the established products in this space? by target, indication, API class, revenue?
What is the competitive TKI picture for the major Oncology market segments?
Drug treatment resources
Competitive therapy map
Clinical trial activity
Who are the leading competitors in the field of next-generation TKI therapeutics?
Key Topics Covered:
Biological Drug Market Dynamics
Tyrosine Kinase Inhibitors
TKI Therapeutics - Breast Cancer (Two Approved TKIs)
Breast Cancers - Clinical Trial Activity
Breast Cancers - Market Data
Gastrointestinal Carcinoid Tumors
Gastrointestinal Stromal Tumors
TKI Therapeutics - Gastrointestinal Cancers (Three Approved TKIs)
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
TKI Therapeutics - Hematology Cancers
TKI Clinical Trial Activity - Hematology Cancers (Seven Approved TKIs)
Hematology Cancers - Market Data
Non-small Cell Lung Cancer
Small Cell Lung Cancer
TKI Therapeutics - Lung Cancers (Thirteen Approved TKIs)
Clinical Trial Activity - Lung Cancers
TKI Therapeutics - Melanoma (Three Approved TKIs)
Melanoma - Clinical Trial Activity
Melanoma - Market Data
Renal Cell Carcinoma
TKI Therapeutics - Renal Cell Carcinoma (Three Approved TKIs)
Renal Cell Carcinoma - Clinical Trial Activity
Renal Cell Carcinoma - Market Data
TKI Therapeutics - Thyroid Cancers (Five Approved TKIs)
Thyroid Cancers - Market Data
Merck Sharp & Dohme
Pierre Fabre Medicament
For more information about this report visit https://www.researchandmarkets.com/r/p5egc4
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900